Navigation Links
Researchers find model system to study promising cancer drug
Date:12/18/2012

Researchers have found that the budding yeast (Saccharomyces cerevisiae) is an acceptable model system to study KP1019, an anti-cancer drug that uses ruthenium, a rare metal, a new study found. Researchers had previously been interested in studying KP1019 because it is believed to cause cancer cell death and is not known to have negative secondary side effects for healthy tissues.

"We wanted to learn more about how KP1019 works on a cellular level, and how the drug acts on yeast cells can be indicative of how it will perform on mammalian cells," said Pamela Hanson, associate professor of biology at Birmingham-Southern College in Alabama. "Besides the economic advantages, there are good scientific reasons to work with yeast, including the abundance of yeast genetic and genomic tools."

In past research, KP1019 has been shown to inhibit ovarian tumor cell production, cause death of colon cancer cells and reduce overall tumor size.

Along with testing the hypothesis that yeast could be a good model system for studying KP1019, researchers wanted to identify how the drug was internalized by cells. KP1019 was taken up within two hours and caused a dose-dependent increase in cell death. It was also found to delay cell proliferation within one hour, most likely the result of KP1019 binding to and damaging DNA.

"More research needs to be done on how KP1019 is internalized," said Hanson. "We suspect that the drug enters cells through more than one route."

Previous studies showed that this drug entered cancer cells, at least in part, through the transferrin-mediated iron-uptake pathway; however, yeast does not contain this specific pathway. Therefore, there must be other means for this drug to enter cells.


'/>"/>
Contact: Scott Willyerd
scott@dickjones.com
330-601-0857
Dick Jones Communications
Source:Eurekalert

Page: 1

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. Researchers develop a new cell and animal model of inflammatory breast cancer
3. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
4. Researchers Find Gene Mutations That May Be a Key to Autism
5. Researchers find evidence of banned antibiotics in poultry products
6. NJ stroke researchers report advances in spatial neglect research at AAN Conference
7. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
8. Researchers Map Brain Regions Linked to Intelligence
9. Researchers ID Genes That May Determine Mental Illness
10. Researchers Develop Blood Test for Depression
11. University of Cincinnati researchers win $3.7M grant from US Department of Defense
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... TX (PRWEB) , ... July 27, 2017 , ... ... and outsourced services, announces the internal promotion of Elrene Clinkscales to Vice President ... – Claims & Remittance Management, reporting to Derek Morkel, chief executive officer (CEO). ...
(Date:7/27/2017)... ... July 27, 2017 , ... Team Novo Nordisk, the world’s first all-diabetes professional ... squad as a stagiaire for the remainder of the 2017 season. One of our ... at the Tour of Utah. , “Every season we are excited to move an ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... is pleased to now offer a major advancement in drug therapy for patients ... Ocrevus (pronounced Ah-creh-vus) is a novel B cell targeted therapy that has ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are dentists and we ... from San Jose, Calif., “so we invented the MAGNETIC/ LOCK BRACKETS.” , The patent-pending ... orthodontic braces. In doing so, it offers an effective alternative to traditional braces. As ...
(Date:7/26/2017)... Baton Rouge, Louisiana (PRWEB) , ... July 26, 2017 , ... ... their doctors to offer the ability for patients to schedule an appointment online in ... LocalMed directly from the Six Month Smiles provider directory will bring more Six Month ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... EXTON, Pa., July 27, 2017  West Pharmaceutical Services, ... financial results for the second-quarter 2017 and updated financial ... Second-Quarter 2017 Highlights Reported ... 2.5% over the prior-year quarter. Net sales at constant ... 2017 reported-diluted EPS was $0.51, compared to $0.60 in ...
(Date:7/26/2017)... NEW YORK , July 26, 2017 ... Annual Prix Galien USA Award ... honors, the Prix Galien Award recognizes outstanding biomedical and technology ... To qualify, each candidate must be ... the last five years and demonstrate tremendous potential to impact ...
(Date:7/24/2017)... 24, 2017  Diplomat Pharmacy, Inc. (NYSE: ... second quarter 2017 operating results on Monday, August 7, ... follow at 5:00 p.m. ET. ... a live broadcast of the conference call by dialing ... code 51641230 approximately 15 minutes prior to the call. ...
Breaking Medicine Technology: